Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.

A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients with non-Hodgkin lymphoma. Doses of 1-20 mg daily were given intravenously for up to 43 days. In both patients lymphoma cells were cleared from the blood and bone marrow and splenomegaly resolved. One p...

Bibliografske podrobnosti
Main Authors:	Hale, G, Dyer, M, Clark, MR, Phillips, J, Marcus, R, Riechmann, L, Winter, G, Waldmann, H
Format:	Journal article
Jezik:	English
Izdano:	1988

Podobne knjige/članki

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
od: Dyer, M, et al.
Izdano: (1990)

Specificity of monoclonal antibody Campath-1.
od: Hale, G, et al.
Izdano: (1988)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
od: Hale, G, et al.
Izdano: (1994)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
od: Dyer, M, et al.
Izdano: (1988)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
od: Waldmann, H, et al.
Izdano: (1985)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
od: Lim, S, et al.
Izdano: (1993)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
od: Waldmann, H, et al.
Izdano: (1985)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
od: Killick, S, et al.
Izdano: (1997)

Reshaping human antibodies for therapy.
od: Riechmann, L, et al.
Izdano: (1988)

The CAMPATH-1 antigen (CDw52).
od: Hale, G, et al.
Izdano: (1990)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
od: Isaacs, J, et al.
Izdano: (1996)

CAMPATH: from concept to clinic.
od: Waldmann, H, et al.
Izdano: (2005)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
od: Naparstek, E, et al.
Izdano: (1999)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
od: Friend, P, et al.
Izdano: (1991)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
od: Williams, R, et al.
Izdano: (2000)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
od: Isaacs, J, et al.
Izdano: (1995)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
od: Dyer, M, et al.
Izdano: (1989)

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection.
od: Rebello, P, et al.
Izdano: (1999)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
od: Hale, G, et al.
Izdano: (1986)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
od: Dyer, M, et al.
Izdano: (1989)

Availability of Campath-1 antibodies for bone marrow transplantation.
od: Hale, G, et al.
Izdano: (1995)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
od: Newman, D, et al.
Izdano: (1995)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
od: Lim, S, et al.
Izdano: (1993)

Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation.
od: Hale, G, et al.
Izdano: (1985)

CAMPATH-1H in inflammatory arthritis.
od: Watts, R, et al.
Izdano: (1993)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
od: Hale, G, et al.
Izdano: (1988)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
od: Hale, G, et al.
Izdano: (1996)

In vivo 'purging' of residual disease in CLL with Campath-1H.
od: Dyer, M, et al.
Izdano: (1997)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
od: Waldmann, H, et al.
Izdano: (1987)

ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR LEUKEMIA USING CAMPATH-1 MONOCLONAL-ANTIBODIES AND POSTTRANSPLANT ALLOIMMUNIZATION WITH DONOR LYMPHOCYTES
od: Naparstek, E, et al.
Izdano: (1993)

CAMPATH-IH in multiple sclerosis.
od: Moreau, T, et al.
Izdano: (1996)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
od: Novitzky, N, et al.
Izdano: (2004)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
od: Xia, M, et al.
Izdano: (1993)

Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy.
od: Lockwood, C, et al.
Izdano: (1993)

Evaluation of non-myeloablative conditioning combining beam with in vivo pre-transplant Campath-IG for allogeneic transplantation in patients with lymphoma.
od: Russell, N, et al.
Izdano: (1999)

CAMPATH-1 antibodies in stem-cell transplantation.
od: Hale, G, et al.
Izdano: (2001)

Appropriate targets for monoclonal antibodies in the induction of transplantation tolerance.
od: Waldmann, H, et al.
Izdano: (2001)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
od: Watts, R, et al.
Izdano: (1992)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
od: Hale, G, et al.
Izdano: (2002)

Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users.
od: Hale, G, et al.
Izdano: (1998)